|
Angiodynamics, Inc. (ANGO) DCF -Bewertung
US | Healthcare | Medical - Instruments & Supplies | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
AngioDynamics, Inc. (ANGO) Bundle
Verbessern Sie Ihre Anlagestrategien mit dem DCF -Taschenrechner des Angiodynamics, Inc. (ANGO)! Erforschen Sie reale Finanzdaten aus der Angiodynamik, passen Sie Wachstumsprojektionen und -kosten an und visualisieren Sie sofort, wie sich diese Veränderungen auf den inneren Wert von Angiodynamics, Inc. (ANGO) auswirken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 264.2 | 291.0 | 316.2 | 338.8 | 303.9 | 315.8 | 328.2 | 341.0 | 354.4 | 368.3 |
| Revenue Growth, % | 0 | 10.17 | 8.66 | 7.13 | -10.28 | 3.92 | 3.92 | 3.92 | 3.92 | 3.92 |
| EBITDA | -143.7 | -8.9 | 11.1 | 12.2 | -14.3 | -34.8 | -36.1 | -37.6 | -39.0 | -40.6 |
| EBITDA, % | -54.41 | -3.06 | 3.52 | 3.6 | -4.7 | -11.01 | -11.01 | -11.01 | -11.01 | -11.01 |
| Depreciation | 23.5 | 26.3 | 29.5 | 33.2 | 27.7 | 29.2 | 30.3 | 31.5 | 32.7 | 34.0 |
| Depreciation, % | 8.89 | 9.03 | 9.33 | 9.79 | 9.12 | 9.23 | 9.23 | 9.23 | 9.23 | 9.23 |
| EBIT | -167.2 | -35.2 | -18.4 | -21.0 | -42.0 | -63.9 | -66.4 | -69.0 | -71.7 | -74.6 |
| EBIT, % | -63.31 | -12.09 | -5.81 | -6.19 | -13.82 | -20.24 | -20.24 | -20.24 | -20.24 | -20.24 |
| Total Cash | 54.4 | 48.2 | 28.8 | 44.6 | 76.1 | 53.4 | 55.4 | 57.6 | 59.9 | 62.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 31.3 | 35.4 | 52.3 | 52.8 | 43.6 | 44.5 | 46.3 | 48.1 | 50.0 | 51.9 |
| Account Receivables, % | 11.84 | 12.17 | 16.54 | 15.59 | 14.35 | 14.1 | 14.1 | 14.1 | 14.1 | 14.1 |
| Inventories | 59.9 | 48.6 | 51.4 | 55.3 | 60.6 | 58.1 | 60.3 | 62.7 | 65.1 | 67.7 |
| Inventories, % | 22.68 | 16.71 | 16.25 | 16.33 | 19.95 | 18.38 | 18.38 | 18.38 | 18.38 | 18.38 |
| Accounts Payable | 19.1 | 19.6 | 28.0 | 40.4 | 37.8 | 29.8 | 31.0 | 32.2 | 33.5 | 34.8 |
| Accounts Payable, % | 7.23 | 6.75 | 8.87 | 11.94 | 12.42 | 9.44 | 9.44 | 9.44 | 9.44 | 9.44 |
| Capital Expenditure | -7.6 | -13.7 | -4.3 | -4.4 | -5.8 | -7.7 | -8.0 | -8.3 | -8.6 | -8.9 |
| Capital Expenditure, % | -2.87 | -4.71 | -1.36 | -1.28 | -1.9 | -2.42 | -2.42 | -2.42 | -2.42 | -2.42 |
| Tax Rate, % | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 |
| EBITAT | -165.9 | -30.8 | -16.3 | -20.2 | -40.4 | -59.8 | -62.2 | -64.6 | -67.1 | -69.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -222.0 | -10.5 | -2.3 | 16.6 | -17.2 | -44.6 | -42.7 | -44.3 | -46.1 | -47.9 |
| WACC, % | 6.84 | 6.83 | 6.83 | 6.84 | 6.84 | 6.84 | 6.84 | 6.84 | 6.84 | 6.84 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -185.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -49 | |||||||||
| Terminal Value | -1,010 | |||||||||
| Present Terminal Value | -726 | |||||||||
| Enterprise Value | -911 | |||||||||
| Net Debt | -71 | |||||||||
| Equity Value | -840 | |||||||||
| Diluted Shares Outstanding, MM | 40 | |||||||||
| Equity Value Per Share | -20.89 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to create various scenarios.
- Real-World Data: AngioDynamics, Inc.'s (ANGO) financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing projections, validating strategies, and saving time.
Key Features
- Comprehensive Financial Data: AngioDynamics' historical financial statements and pre-populated projections.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: View AngioDynamics' intrinsic value recalculated instantly.
- Intuitive Visualizations: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A professional-grade tool tailored for analysts, investors, and finance professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing AngioDynamics, Inc.'s (ANGO) preloaded financial data.
- 2. Modify Key Inputs: Adjust essential parameters such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results Immediately: The DCF model automatically computes the intrinsic value and NPV based on your inputs.
- 4. Explore Different Scenarios: Evaluate various forecasts to understand potential valuation variations.
- 5. Present with Assurance: Deliver expert valuation insights to enhance your decision-making process.
Why Choose AngioDynamics, Inc. (ANGO) Solutions?
- Enhance Efficiency: Our tools streamline processes, eliminating the need for complex setups.
- Boost Precision: Access to accurate data and methodologies minimizes discrepancies in your assessments.
- Completely Adaptable: Modify our solutions to align with your specific needs and forecasts.
- User-Friendly: Intuitive interfaces and visualizations facilitate straightforward analysis of results.
- Endorsed by Professionals: Crafted for experts who prioritize accuracy and functionality.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling AngioDynamics, Inc. (ANGO) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for AngioDynamics, Inc. (ANGO).
- Consultants: Deliver professional valuation insights on AngioDynamics, Inc. (ANGO) to clients quickly and accurately.
- Business Owners: Understand how companies like AngioDynamics, Inc. (ANGO) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to AngioDynamics, Inc. (ANGO).
What the Template Contains
- Historical Data: Includes AngioDynamics, Inc.'s (ANGO) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate AngioDynamics, Inc.'s (ANGO) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of AngioDynamics, Inc.'s (ANGO) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.